Zhitong Finance App News, China Biopharmaceutical (01177.HK) announced that the TQC3721 suspension “PDE3/4 inhibitor”, a class 1 innovative drug developed by the Group, has been approved by the Drug Evaluation Center (CDE) of the China National Drug Administration (CDE) to conduct phase III registered clinical studies for maintenance treatment of chronic obstructive pulmonary disease (COPD).

Zhitongcaijing · 06/09 11:49
Zhitong Finance App News, China Biopharmaceutical (01177.HK) announced that the TQC3721 suspension “PDE3/4 inhibitor”, a class 1 innovative drug developed by the Group, has been approved by the Drug Evaluation Center (CDE) of the China National Drug Administration (CDE) to conduct phase III registered clinical studies for maintenance treatment of chronic obstructive pulmonary disease (COPD).